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ABSTRACT. Objective. To assess the usefulness of a
polymerase chain reaction (PCR) assay amplifying the
small subunit rRNA coding region of Leishmania species
performed on peripheral blood (PB) and bone marrow
(BM) aspirates for the diagnosis and follow-up of vis-
ceral leishmaniasis (VL) in children living in the Medi-
terranean basin.
Design. A prospective study was conducted on chil-
dren consecutively hospitalized over a 1-year period at
our Infectious Diseases Department in Sicily (Italy) pre-
senting with fever, hepatosplenomegaly, and/or pancyto-
penia and a positive Leishmania serology (>1:40).
Results. Among the 14 patients hospitalized with
signs and symptoms suggestive of the disease and a
positive serology, we identified 10 cases of Mediterra-
nean VL. PCR performed on PB and BM aspirates was
positive in all cases and concordant with microscopy
and/or culture performed on BM. Leishmania DNA was
cleared from PB a median of 6 days after the start of
treatment; during follow-up (median: 9 months; range:
6–12 months) 1 child relapsed. In this case, BM PCR
remained positive with rapid reappearance of a positive
signal also in PB.
Conclusions. PB PCR allows a rapid and noninvasive
parasitologic diagnosis of Mediterranean VL among im-
munocompetent children and is at least as sensitive as a
diagnosis made on the basis of BM aspirates. The lack of
disappearance from BM and the reappearance of positive
PCR on PB is predictive of clinical relapse. Qualitative
and semiquantitative PCR may be the standard method
for monitoring response to therapy in immunocompe-
tent children. Pediatrics 2002;109(2). URL: http://www.
pediatrics.org/cgi/content/full/109/2/e27; visceral leish-
maniasis, polymerase chain reaction, diagnosis, peripheral
blood, bone marrow.
ABBREVIATIONS. VL, visceral leishmaniasis; BMA, bone mar-
row aspirate; PB, peripheral blood; PCR, polymerase chain reac-
tion; HIV, human immunodeficiency virus; RFLP, restriction frag-
ment length polymorphism; BM, bone marrow.
Visceral leishmaniasis (VL) attributable toLeishmania infantum is a vector-borne zoonoticdisease transmitted by sand fly bites and is
endemic in rural or periurban areas of the Mediter-
ranean basin.1 Before the age-related changes intro-
duced by the acquired immunodeficiency syndrome
epidemic in southern European countries, VL mainly
affected children younger than 5 years.2,3 However,
an epidemiologic survey conducted in Sicily between
1987 and 1995 revealed that 53% of all cases were still
observed in children younger than 14 years of age.4
In 2 recent retrospective pediatric studies conducted
in France and Greece, the median age of patients was
2 years, 5 months.5,6 The most common methods of
diagnosing VL are classic parasitologic methods such
as microscopic direct examination and in vitro cul-
ture of bone marrow aspirates (BMAs). As these
techniques require invasive procedures and are dif-
ficult to repeat for follow-up of patients, an easy,
rapid, and noninvasive method would be valuable.
In this regard, polymerase chain reaction (PCR) used
on peripheral blood (PB) of patients with VL (mainly
human immunodeficiency virus [HIV]-Leishmania
coinfected adults) has proved highly specific and
sensitive.7–9 Therefore, we conducted a prospective
study among all children hospitalized for suspected
Mediterranean VL during a 1-year period to assess
the usefulness of Leishmania PCR in the first diagno-
sis and follow-up of VL in childhood.
METHODS
Study Design
All consecutive patients admitted to the Institute of Infectious
Pathology and Virology of the University of Palermo between
November 1999 and November 2000 with fever, hepatospleno-
megaly pancytopenia, and a positive serology for Leishmania were
enrolled in the study. A definitive diagnosis of VL was based on
the presence of at least 1 of the following criteria: 1) direct micro-
scopic demonstration of Leishmania amastigotes in the BMA
and/or 2) culture isolation of promastigotes from BMAs inocu-
lated into selective medium.
BMAs were performed at the time of diagnosis and 4 weeks
after treatment initiation (in the case of confirmed VL); PB samples
were collected at the time of diagnosis (T0), every 3 days (T1, T2,
T3, T4) for 2 weeks and then at weekly intervals for 2 weeks;
thereafter, PB samples were obtained at month 3, 6, 9, and 12
unless a clinical relapse occurred before this period.
In all cases, the DNA extracted from ethylenediaminetetraacetic
acid-anticoagulated PB and BMA was assayed for Leishmania spe-
cies DNA by means of a PCR (that proved highly sensitive and
specific) as described elsewhere.9 Identification of the Leishmania
at the species level was obtained by restriction fragment length
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polymorphism (RFLP) analysis of a repetitive Leishmania-specific
nuclear genomic sequence obtained as described by Minodier et
al.9–11 When available, identification results were compared with
the standard isoenzyme characterization data.12
Serology was obtained by means of indirect immunofluores-
cence antibody test using a commercial kit (Leishmania Spot IF,
Biomerieux, Marcy L’Etoile, France) and was performed at the
time of diagnosis, 4 weeks later, and at each patient’s last fol-
low-up visit.
All of the patients with VL were randomly assigned to a spe-
cific anti-Leishmania treatment as a part of a multicenter treatment
study coordinated by the Istituto Superiore di Sanita`, Rome, Italy,
and designed to compare a pentavalent antimonial (meglumine
antimoniate, Glucantim, Aventis Pharma, Milan, Italy) at a dose of
20 mg Sb5/kg/day given intramuscularly for 28 days versus lipo-
somal amphotericin B (Ambisome, Gilead, San Diego, CA) at a
dose of 3 mg/kg/day intravenously for 5 days followed by 1
additional administration after 1 week.
The study was approved by the local ethics committee, and the
parents gave informed consent before the enrollment of the chil-
dren in the study.
RESULTS
One hundred fourteen PB and 27 bone marrow
(BM) samples taken from 14 immunocompetent chil-
dren were tested. Overall, 10 patients were diag-
nosed as having VL; the remaining 4 patients (all of
whom underwent bone marrow aspiration) had
acute leukemia (2 cases) and infectious mononucle-
osis (2 cases). PCR performed either on PB and BMA
in these 4 patients had negative results. Table 1 sum-
marizes the parasitologic, serologic Leishmania zymo-
deme, and PCR studies conducted on the patients
with confirmed VL. In all cases, PCR detected Leish-
mania in all BM (9/9) and PB (10/10) samples at first
diagnosis; semiquantitative PCR analysis showed
that the parasite load was at least 1 log higher in the
BM samples of 8 cases (Fig 1), and comparable with
the PB and BM samples of the remaining 2 patients.
Microscopy revealed Leishmania amastigotes in 9 of
10 BM samples, whereas culture gave positive results
in 8 of 8 cases. PCR-RFLP analysis for Leishmania
species identification was performed for all patients
and showed a single 250-bp band suggestive of L
infantum infection (Fig 2). Eight Leishmania stocks
isolated in culture from BMAs were identified by
isoenzyme analysis as L infantum zymodeme MON1.
The patients were monitored during and after
treatment for a median of 9 months (range: 6–12
months). The PB parasitemia detected by PCR was
short-lived, and in all patients the assay became neg-
ative after a median of 6 days. However, the clear-
ance of PB parasitemia was more rapid and statisti-
cally significant in the patients treated with
liposomal amphotericin than in those treated with
meglumine antimoniate (median: 6 days vs 14 days;
P  .03: Mann-Whitney U test). Leishmania PCR on
PB remained negative during the follow-up in all but
1 patient (who is described in greater detail below).
During the follow-up anti-Leishmania serology was
unrevealing; in fact, 1 month after the first diagnosis,
antibody titers remained unchanged (4 patients) or
showed a slight decrease (6 patients). At the last
follow-up visit, serology reverted to negativity in 1
patient only, whereas the antibody titers were still
unchanged in 2 children, had increased in 2, and had
decreased in the remaining 5 patients. TA
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Case 10
A 9-month-old child was admitted to our ward
with a 15-day history of high fever (40°C) and cough.
On physical examination, he was febrile and pale,
and had an enlarged liver (5 cm below the right
costal margin), and splenomegaly (8 cm below the
left costal margin). Laboratory values were as fol-
lows: hemoglobin: 8.7 g/dL; platelets 98.000/L; and
C-reactive protein: 2 mg/dL. Leishmania serology
was positive at a titer of 1:320; a BMA showed sev-
eral Leishmania amastigotes. The patient was ran-
domized to receive a 28-day course of meglumine
antimoniate (60 mg/kg/d, total dose 504 mg). Defer-
vescence occurred on the sixth day of therapy. At the
end of the treatment PB PCR was negative, the he-
matologic values had risen (Hb 10.2 g/dL; platelets
252.000/L), and the hepatosplenomegaly was re-
duced. No culture was performed, but microscopic
examination of a posttreatment BMA indicated par-
asitologic cure and so the patient was discharged
despite the fact that PCR on BM was still positive. At
the first follow-up visit (third month), the child was
in apparent good health and still afebrile, and his
weight had increased from 8.4 kg to 12 kg. At this
time, PCR on PB was again positive. Fifteen days
later, the child was readmitted to our hospital with
persistent fever (39 °C), an enlarged spleen (5 cm
below the left costal arch), and anemia (Hb 8.8 g/dL).
An additional BMA showed numerous intracellular
and extracellular Leishmania amastigotes; the PB and
BM PCRs were still positive with the latter showing
an increase of parasite load in comparison with the
pretreatment sample (Fig 1). The patient was treated
with liposomal amphotericin B (Ambisome 3 mg/
kg/d) for 10 days and showed defervescence on the
third day. PCR on PB became negative 1 week after
the start of treatment. One month later, microscopy
of BM smears was negative and both BM and PB
Fig 1. Kinetics of L infantum DNA disappearance and relapse in PB and BM of 10 children with VL under specific therapy as determined
by PCR.
Fig 2. RFLP analysis of a Leishmania-specific nuclear repetitive
genomic sequence amplified in vivo from PB of infected children
by PCR. PCR products were purified and digested with the re-
striction enzyme HaeIII. Lane 1 is a molecular weight marker.
Lanes 2 and 3 represent 2 children with L infantum parasitemia.
Lanes 4 and 5, respectively, were obtained after digestion of PCR
products using DNA extracted from in vitro isolated L donovani
and L infantum reference strains.
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were PCR-negative; at the last follow-up visit (4
months after the new treatment) PB PCR was still
negative.
DISCUSSION
PCR on PB, BM, and lymph node aspirates has
been increasingly used as a rapid, sensitive, and
specific method for the diagnosis of VL mainly in
immunocompromised patients.7–9,13 In immunocom-
petent host, Nuzum et al14 have reported a 90%
sensitivity of PB PCR in parasitologically confirmed
cases of kala-azar from 2 areas endemic for Leishma-
nia donovani (India and Africa) and 1 endemic for
Leishmania chagasi (Brazil). Other researchers from
Sudan detected Leishmania DNA by PCR in the PB of
70% of their patients with confirmed VL.15
To the best of our knowledge, the use of PCR
performed on PB (whole blood and buffy coat) and
BMA for the diagnosis of VL in pediatric patients has
been previously reported in the case of 13 children
from France5,8 and 12 from China.16 In the former
study, Minodier et al5 detected Leishmania DNA by
PCR in 5 of 5 BM samples and 3 of 7 PB samples
taken from 8 children with VL. In a more recent
study from France,17 the investigators reported con-
cordant and positive PCR results on PB and BM
samples from 3 immunocompetent children (in 1
case, the cultures remained negative and diagnosis
was confirmed by other methods), and concordant
positive PCR and culture results in 1 patient for
whom only PB was available. In the study conducted
in China, primary or nested PCR was positive on 9 of
10 BM and in 7 of 11 PB (buffy coat) specimens.
The aims of our study were to compare the results
of PB and BM PCR with those of standard parasito-
logic methods of diagnosing VL and, mainly, to eval-
uate the usefulness of this molecular method in as-
sessing definitive parasitologic cure after treatment.
Our results confirm the reliability of Leishmania PCR
performed on PB in the diagnosis of VL; the high
level of sensitivity was reflected by the ability of the
assay to detect parasite DNA in PB of patients with
VL in all cases, a result that was better than micros-
copy and equal to culture performed on BMAs.
Our results also show that parasitemia in PB is
usually short-lived in immunocompetent children
receiving antileishmanial treatment (a median of 6
days to achieve PCR negativity). In addition, we
demonstrated that the persistence of a positive BM
PCR is followed by the rapid reappearance of Leish-
mania parasites in PB and, ultimately, clinically overt
disease relapse. As expected, in the majority of cases
(all but 2 patients), the PB parasite load was less than
in BM; furthermore, the rapid disappearance of PB
parasitemia in this group of immunocompetent chil-
dren contrasts with what we have previously ob-
served in immunocompromised HIV-positive pa-
tients, in whom PB parasitemia became negative
under treatment after a median of 5 weeks.9 Al-
though in our study the number of treated children
with the 2 regimes was limited, we observed a sta-
tistically significant more rapid clearance of blood
parasitemia in the group assigned to liposomal am-
photericin B; however, larger series of patients
should be examined before any definitive conclu-
sions can be drawn concerning the relative efficacy of
either drug.
It has long been accepted that few or no circulating
Leishmania parasites are present in patients with
Mediterranean VL. However, a number of recent
studies have reported the detection L infantum in PB
of patients coinfected with HIV.18–20 Our study con-
firms the frequent presence of circulating parasites
during the course of VL also in immunocompetent
individuals17 and extends this finding to immuno-
competent children. Moreover, PCR-RFLP analysis
identified the etiologic agent as L infantum in all
cases, a finding later confirmed by the standard
method of Leishmania biochemical characterization.
Physicians are probably still not confident about
replacing BM examination with PB PCR for the di-
agnosis of VL. However, we believe that this method
should be considered the gold standard for monitor-
ing parasitologic cure because it is easy to perform,
noninvasive (thus allowing frequent sampling), well
accepted by patients (especially children), and more
reliable than microscopy and serology, and more
rapid than traditional culture. Finally, patient moni-
toring by means of Leishmania-specific PCR in the
blood can predict treatment failure in a timely man-
ner, and thus allow prompt and appropriate thera-
peutic adjustments.
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